BIIE-0246
BIIE-0246 is a selective neuropeptide Y receptor antagonist that has been studied for its potential effects on anxiety, depression, and feeding behavior. It specifically targets the Y2 receptor subtype, which is one of the several receptor subtypes for the neuropeptide Y (NPY) family.
Chemical Properties[edit | edit source]
BIIE-0246 is a synthetic compound with a complex chemical structure designed to selectively inhibit the Y2 receptor. The chemical name and molecular formula of BIIE-0246 are as follows:
- Chemical Name:
- Molecular Formula:
Mechanism of Action[edit | edit source]
BIIE-0246 functions by binding to the Y2 receptor, thereby blocking the action of neuropeptide Y. The Y2 receptor is primarily involved in the regulation of neurotransmitter release, particularly in the central nervous system. By inhibiting this receptor, BIIE-0246 can modulate various physiological processes, including anxiety, depression, and appetite.
Pharmacological Effects[edit | edit source]
Studies have shown that BIIE-0246 can produce anxiolytic and antidepressant-like effects in animal models. It has also been observed to influence feeding behavior, potentially reducing food intake by modulating the signaling pathways associated with hunger and satiety.
Anxiety and Depression[edit | edit source]
Research indicates that BIIE-0246 may have therapeutic potential in the treatment of anxiety disorders and depression. By blocking the Y2 receptor, it can alter the release of neurotransmitters such as serotonin and norepinephrine, which are critical in mood regulation.
Feeding Behavior[edit | edit source]
BIIE-0246 has been studied for its effects on feeding behavior. The Y2 receptor plays a significant role in the regulation of appetite, and antagonism of this receptor by BIIE-0246 can lead to reduced food intake, making it a potential candidate for the treatment of obesity and related metabolic disorders.
Research and Development[edit | edit source]
BIIE-0246 is primarily used in preclinical research to understand the role of the Y2 receptor in various physiological and pathological processes. Its selective antagonism makes it a valuable tool for dissecting the specific functions of the Y2 receptor in the central nervous system and peripheral tissues.
Potential Therapeutic Applications[edit | edit source]
While BIIE-0246 is not currently approved for clinical use, its pharmacological profile suggests potential applications in the treatment of anxiety disorders, depression, and obesity. Further research is needed to fully understand its therapeutic potential and safety profile.
See Also[edit | edit source]
References[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD